Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Inspiratory Muscle Training Plus Cold Water Immersion After Muscle-Damaging Exercise

3. november 2026 oppdatert av: Mete Berk Demiryol, University of Gaziantep

The Combined Effect of Cold Water Immersion and Inspiratory Muscle Training on the Recovery From Exercise-Induced Muscle Damage and Physical Performance: A Randomized, Placebo-Controlled Crossover Study

The purpose of this study is to examine, using a placebo-controlled design, the additional effect of inspiratory muscle training (IMT) added to cold water immersion (CWI) on recovery and muscle performance following exercise-induced muscle damage (EIMD), and to determine whether this effect varies depending on the timing of the intervention. The study will include 12 healthy male athletes aged 18-22 who have been licensed for at least 4 years and are actively involved in sports. Each participant will undergo four different interventions in a randomized order determined by the Williams balanced sequence following muscle damage induced by eccentric exercise on an isokinetic dynamometer: CWI + placebo IMT immediately after exercise, IMT + CWI immediately after exercise, IMT + CWI 24 hours after exercise, and a control condition with no recovery intervention. The sessions will be conducted in weekly cycles with 7-day intervals, alternating between the dominant and non-dominant legs; thus, there will be a 14-day interval between two loading sessions for the same leg. All measurements will be taken during the week. Muscle strength will be assessed using an isokinetic dynamometer; markers of muscle damage (CK, myoglobin, LDH) will be measured via blood samples; and muscle pain will be evaluated using the Visual Analog Scale (VAS) before each exercise session and 48 hours after exercise.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Şehitkamil
      • Gaziantep, Şehitkamil, Tyrkia (Türkiye)
        • Gaziantep University, Faculty of Sports Sciences, Sports Performance and Testing Laboratory

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 22 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  • Be a male between the ages of 18 and 22
  • Hold a sports license valid for at least 4 years
  • Be actively involved in sports
  • Not smoke or use similar substances

Exclusion Criteria:

  • Having sustained a sports injury within the past 2 years
  • Having engaged in exercise that could cause muscle damage within the past 15 days
  • Cold intolerance, cold urticaria, or Raynaud's phenomenon
  • Known cardiovascular, respiratory, or musculoskeletal disease
  • Use of anti-inflammatory medication or dietary supplements that could affect recovery during the study period

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Sham-komparator: CWI + placebo IMT

Device: Placebo IMT - 2 × 30 breaths at 15% of MIP using POWERbreathe (1 min between sets), immediately following the short test after EIMD. Other: Immersion in cold water - immediately following the placebo IMT, in 10-12 °C water, up to waist level or with legs fully submerged, for 10-15 minutes.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Same device, position and volume as inspiratory muscle training (two sets of 30 breaths, 1 minute rest), but at 15% of maximal inspiratory pressure, a load considered below the training threshold. Followed immediately by cold water immersion.

Eksperimentell: IMT + CWI (immediately)

Other: Inspiratory muscle training + cold water immersion. Immediately following the short test after EIMD, 2 × 30 breaths at 40% of MIP using POWERbreathe (1 min rest between sets), followed by CWI.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Eksperimentell: IMT + CWI (at 24 hours)

Other: Inspiratory muscle training + cold water immersion. The same IMT and CWI protocol is administered 24 hours after EIMD; the 48-hour measurement is taken relative to EIMD (24 hours after the intervention).

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Ingen inngripen: Control

No recovery procedure is performed after the EIMD protocol; only measurements are taken.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Peak Power ( 60°/s)
Tidsramme: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 5-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Peak Power ( 180°/s)
Tidsramme: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 10-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Average Power ( 180°/s- 60°/s)
Tidsramme: The 48-hour period before and after EIMD in each phase

Average of peak torque values during test repetitions (Nm)

The 48-hour period before and after EIMD in each phase
Serum creatine kinase (CK)
Tidsramme: The 48-hour period before and after EIMD in each phase

CK level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase
Myoglobin (Mb)
Tidsramme: The 48-hour period before and after EIMD in each phase

Myoglobin level in venous blood (ng/mL)

The 48-hour period before and after EIMD in each phase
Lactate dehydrogenase (LDH)
Tidsramme: The 48-hour period before and after EIMD in each phase

LDH level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
H/Q ratio
Tidsramme: The 48-hour period before and after EIMD in each phase

Hamstring-to-quadriceps peak torque ratio (60°/s and 180°/s)

The 48-hour period before and after EIMD in each phase
VAS
Tidsramme: During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD

0-10 cm Visual Analog Scale (0 = no pain, 10 = very severe pain)

During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD
Fatique Index
Tidsramme: The 48-hour period before and after EIMD in each phase

Fatigue index (%) calculated from a test consisting of 10 cycles at 180°/s

The 48-hour period before and after EIMD in each phase

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

31. desember 2026

Studiet fullført (Antatt)

31. desember 2026

Datoer for studieregistrering

Først innsendt

27. oktober 2026

Først innsendt som oppfylte QC-kriteriene

3. november 2026

Først lagt ut (Faktiske)

9. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026/9504

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

"Individual participant data will not be shared for privacy reasons; aggregate results will be published."

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere